MedTrace Logo

Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy

NCT01301391 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-02-06

Study results available
· View outcomes & findings →

Summary

The intent of the study is to assess the antitumor activity of PHA-848125AC in patients with recurrent or metastatic, unresectable malignant thymoma previously treated with multiple lines of chemotherapy.

Conditions

  • Malignant Thymoma

Interventions

DRUG

Milciclib Maleate

150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle. Number of cycles: until disease progression or unacceptable toxicity.

Sponsors & Collaborators

  • Tiziana Life Sciences LTD

    lead INDUSTRY

Principal Investigators

  • Arun Rajan, MD. · National Cancer Institute (NCI)

  • Marina C. Garassino, MD. · Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

  • Giuseppe Giaccone, MD · MedStar Gergetown University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-02
Primary Completion
2017-05-31
Completion
2018-12-17

Countries

  • United States
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01301391 on ClinicalTrials.gov